Michael R. Jaff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael R. Jaff has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alan T. Hirsch
Division of Epidemiology, University of Minnesota School of Public Health, and Vascular Medicine Program, Minneapolis Heart Institute, Rochester, MN, USA
1 shared publication - Alexander S Tretinyak
Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, USA
1 shared publication Gary Ansel
Cardiology, Riverside Hospital, Columbus, OH
1 shared publication- Hak Hong Keo
Vascular Institute Central Switzerland, Aarau, Switzerland
1 shared publication - Iris Baumgartner
Universitätsspital Bern, Inselspital
1 shared publication - James M. Peacock
Cardiovascular Health Unit, Health Promotion and Chronic Disease Division, Minnesota Department of Health, St Paul, Minnesota
1 shared publication
Latest Publications
- Open Access
- 19 December 2013
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 13 (1) , 120
The FReedom from Ischemic Events - New Dimensions for Survival (FRIENDS) registry: design of a prospective cohort study of patients with advanced peripheral artery disease
Advanced lower extremity peripheral artery disease (PAD), whether presenting as acute limb ischemia (ALI) or chronic critical limb ischemia (CLI), is associated with high rates of cardiovascular ischemic events, amputation, and death. Past research has focused on strategies of revascularization, but few data are available that prospectively evaluate the impact of key process of care factors (spanning pre-admission, acute hospitalization, and post-discharge) that might contribute to improving short and long-term health outcomes. The FRIENDS registry is designed to prospectively evaluate a range of patient and health system care delivery factors that might serve as future targets for efforts to improve limb and systemic outcomes for patients with ALI or CLI. This hypothesis-driven registry was designed to evaluate the contributions of: (i) pre-hospital limb ischemia symptom duration, (ii) use of leg revascularization strategies, and (iii) use of risk-reduction pharmacotherapies, as pre-specified factors that may affect amputation-free survival. Sequential patients would be included at an index “vascular specialist-defined” ALI or CLI episode, and patients excluded only for non-vascular etiologies of limb threat. Data including baseline demographics, functional status, co-morbidities, pre-hospital time segments, and use of medical therapies; hospital-based use of revascularization strategies, time segments, and pharmacotherapies; and rates of systemic ischemic events (e.g., myocardial infarction, stroke, hospitalization, and death) and limb ischemic events (e.g., hospitalization for revascularization or amputation) will be recorded during a minimum of one year follow-up. The FRIENDS registry is designed to evaluate the potential impact of key factors that may contribute to adverse outcomes for patients with ALI or CLI. Definition of new “health system-based” therapeutic targets could then become the focus of future interventional clinical trials for individuals with advanced PAD.
- 19 December 2013
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 13 (1) , 120
Open AccessThe FReedom from Ischemic Events - New Dimensions for Survival (FRIENDS) registry: design of a prospective cohort study of patients with advanced peripheral artery disease
Advanced lower extremity peripheral artery disease (PAD), whether presenting as acute limb ischemia (ALI) or chronic critical limb ischemia (CLI), is associated with high rates of cardiovascular ischemic events, amputation, and death. Past research has focused on strategies of revascularization, but few data are available that prospectively evaluate the impact of key process of care factors (spanning pre-admission, acute hospitalization, and post-discharge) that might contribute to improving short and long-term health outcomes. The FRIENDS registry is designed to prospectively evaluate a range of patient and health system care delivery factors that might serve as future targets for efforts to improve limb and systemic outcomes for patients with ALI or CLI. This hypothesis-driven registry was designed to evaluate the contributions of: (i) pre-hospital limb ischemia symptom duration, (ii) use of leg revascularization strategies, and (iii) use of risk-reduction pharmacotherapies, as pre-specified factors that may affect amputation-free survival. Sequential patients would be included at an index “vascular specialist-defined” ALI or CLI episode, and patients excluded only for non-vascular etiologies of limb threat. Data including baseline demographics, functional status, co-morbidities, pre-hospital time segments, and use of medical therapies; hospital-based use of revascularization strategies, time segments, and pharmacotherapies; and rates of systemic ischemic events (e.g., myocardial infarction, stroke, hospitalization, and death) and limb ischemic events (e.g., hospitalization for revascularization or amputation) will be recorded during a minimum of one year follow-up. The FRIENDS registry is designed to evaluate the potential impact of key factors that may contribute to adverse outcomes for patients with ALI or CLI. Definition of new “health system-based” therapeutic targets could then become the focus of future interventional clinical trials for individuals with advanced PAD.
- 8 June 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 70 (3) , 460-462
Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices
Objectives: Define the prospective surveillance and reporting parameters for assessment of metallic stents used in clinical trials of superficial femoral artery atherosclerosis.Background: While advances in medical therapies to improve atherosclerotic risk factor profiles in patients with peripheral arterial disease have focused on prevention of disease progression, the development of endovascular devices is altering the therapeutic algorithm for patients with peripheral arterial disease. Stents have emerged as one of the advances that may promote durable patency, particularly in the infrainguinal arteries.Methods: The Zilver‐PTX is a prospective multicenter randomized trial of bare metal versus drug‐eluting nitinol stents for superficial femoral artery peripheral arterial disease. A predefined surveillance program is mandated in this trial. During the genesis of this program, it became clear that no single standard has existed to identify, classify, and report fractures of metallic stents placed in peripheral arteries.Results: This report defines the key components of prospective stent fracture surveillance, including location of radiographic images obtained, types of radiographic equipment, methods of limb, and image intensifier positioning, intervals required for imaging, grading schemes for reporting, and methods of analyzing the images.Conclusions: As the proliferation of minimally invasive revascularization strategies continues, the stability of metallic endoprostheses is increasingly critical. Uniform surveillance of these devices for fracture and disarticulation is important in order to compare the relative merits of various stent‐based devices in clinical trials.
- 8 June 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 70 (3) , 460-462
Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices
Objectives: Define the prospective surveillance and reporting parameters for assessment of metallic stents used in clinical trials of superficial femoral artery atherosclerosis.Background: While advances in medical therapies to improve atherosclerotic risk factor profiles in patients with peripheral arterial disease have focused on prevention of disease progression, the development of endovascular devices is altering the therapeutic algorithm for patients with peripheral arterial disease. Stents have emerged as one of the advances that may promote durable patency, particularly in the infrainguinal arteries.Methods: The Zilver‐PTX is a prospective multicenter randomized trial of bare metal versus drug‐eluting nitinol stents for superficial femoral artery peripheral arterial disease. A predefined surveillance program is mandated in this trial. During the genesis of this program, it became clear that no single standard has existed to identify, classify, and report fractures of metallic stents placed in peripheral arteries.Results: This report defines the key components of prospective stent fracture surveillance, including location of radiographic images obtained, types of radiographic equipment, methods of limb, and image intensifier positioning, intervals required for imaging, grading schemes for reporting, and methods of analyzing the images.Conclusions: As the proliferation of minimally invasive revascularization strategies continues, the stability of metallic endoprostheses is increasingly critical. Uniform surveillance of these devices for fracture and disarticulation is important in order to compare the relative merits of various stent‐based devices in clinical trials.
- 1 November 2002
- Published by Elsevier in Cardiology Clinics
- Vol. 20 (4) , 491-500
Lower extremity arterial disease
- 1 November 2002
- Published by Elsevier in Cardiology Clinics
- Vol. 20 (4) , 491-500
Lower extremity arterial disease
- 1 November 2002
- Published by SAGE Publications in Angiology
- Vol. 53 (6) , 627-633
Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options
Although endovascular therapy has revolutionized the management of patients with peripheral arterial disease (PAD), noninterventional regimens, such as structured exercise therapy, ath erosclerotic risk factor modification, and pharmacotherapy, are effective in patients suffering from mild-to-moderate PAD and intermittent claudication (IC). For more than a decade, the only pharmacologic therapy for IC available in the United States was pentoxifylline, which had demonstrated superiority in improving walking distances but offered minimal clinical benefit. Recently, basic research into the pathophysiology of IC has led to the development of cilostazol, a new pharmacologic agent approved for treatment of this condition in 1999. Ongoing research in the use of angiogenic growth factors has further broadened the range of potential alternatives to treatment in patients with PAD. Revascularization procedures, including nonsurgical and surgical techniques, can thus be reserved to improve patency and reduce the risk of limb loss in patients with PAD and IC with more severe impairment.
- 1 November 2002
- Published by SAGE Publications in Angiology
- Vol. 53 (6) , 627-633
Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options
Although endovascular therapy has revolutionized the management of patients with peripheral arterial disease (PAD), noninterventional regimens, such as structured exercise therapy, ath erosclerotic risk factor modification, and pharmacotherapy, are effective in patients suffering from mild-to-moderate PAD and intermittent claudication (IC). For more than a decade, the only pharmacologic therapy for IC available in the United States was pentoxifylline, which had demonstrated superiority in improving walking distances but offered minimal clinical benefit. Recently, basic research into the pathophysiology of IC has led to the development of cilostazol, a new pharmacologic agent approved for treatment of this condition in 1999. Ongoing research in the use of angiogenic growth factors has further broadened the range of potential alternatives to treatment in patients with PAD. Revascularization procedures, including nonsurgical and surgical techniques, can thus be reserved to improve patency and reduce the risk of limb loss in patients with PAD and IC with more severe impairment.
- 1 June 2002
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 4 (3) , 239-245
Pseudoaneurysms
Vascular complications that are the result of invasive diagnostic or therapeutic procedures requiring arterial access occur frequently. A common complication, pseudoaneurysm, has significant risk of expansion, extrinsic compression on native arteries, rupture, embolization, and infection. A pseudoaneurysm represents a persistent defect in the walls of the artery, resulting in extravasation of blood outside of the artery. This extravascular blood is confined to the surrounding soft tissues. Clinical suspicion and duplex ultrasonography are the primary diagnostic modalities. There are several options for treatment of pseudoaneurysms, including surgical repair and ultrasound-guided compression. However, a new therapeutic option, ultrasound-guided thrombin injection, has become the treatment of choice for pseudoaneurysms. This procedure is highly effective, rapid, and very safe. Using direct, real-time visualization of the pseudoaneurysm, a needle is inserted percutaneously into the pseudoaneurysm sac, and a small amount of dilute bovine thrombin is injected. Thrombosis of the sac is rapidly evident. Rare complications include thromboembolism into the native artery and hypersensitivity reaction to bovine thrombin.
- 1 June 2002
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 4 (3) , 239-245
Pseudoaneurysms
Vascular complications that are the result of invasive diagnostic or therapeutic procedures requiring arterial access occur frequently. A common complication, pseudoaneurysm, has significant risk of expansion, extrinsic compression on native arteries, rupture, embolization, and infection. A pseudoaneurysm represents a persistent defect in the walls of the artery, resulting in extravasation of blood outside of the artery. This extravascular blood is confined to the surrounding soft tissues. Clinical suspicion and duplex ultrasonography are the primary diagnostic modalities. There are several options for treatment of pseudoaneurysms, including surgical repair and ultrasound-guided compression. However, a new therapeutic option, ultrasound-guided thrombin injection, has become the treatment of choice for pseudoaneurysms. This procedure is highly effective, rapid, and very safe. Using direct, real-time visualization of the pseudoaneurysm, a needle is inserted percutaneously into the pseudoaneurysm sac, and a small amount of dilute bovine thrombin is injected. Thrombosis of the sac is rapidly evident. Rare complications include thromboembolism into the native artery and hypersensitivity reaction to bovine thrombin.